Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index
- PMID: 16236878
- DOI: 10.1378/chest.128.4.2223
Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index
Abstract
Study objectives: To evaluate the usefulness of procalcitonin serum levels as a predictor of etiology and prognosis in adult patients with community-acquired pneumonia (CAP) when they are stratified according to severity.
Design: One-year, population-based, prospective study.
Setting: University teaching hospital.
Patients: All adult patients who received a diagnosis of CAP throughout the study period.
Interventions and measurements: An extensive noninvasive microbiological workup was performed. In patients who gave informed consent, a blood sample was collected at the time the diagnosis of CAP was established to measure biological markers. Procalcitonin levels were measured by a commercially available monoclonal immunoluminometric assay (limit of detection, 0.1 microg/L). Patients were classified according to microbial diagnosis, Patients Outcome Research Team pneumonia severity index (PSI), and outcome measures, and procalcitonin levels were compared among groups.
Results: Of 240 patients who received a diagnosis of CAP during the study period, procalcitonin concentrations were measured in 185 patients (77.1%). Levels were higher in patients with high-severity risk classes (PSI classes III-V) [p = 0.01] and in those with complications (p = 0.03) or death (p < 0.0001). Among patients classified into PSI low-severity risk classes (classes I-II), levels tended to be higher in those with bacterial etiology (p = 0.08); in this group, a serum procalcitonin level > or = 0.15 microg/L was more frequently found in patients with bacterial pneumonia than in those with nonbacterial pneumonia (p = 0.03). In patients with higher-severity risk classes, no significant differences were observed in procalcitonin levels among etiologic groups, but higher concentrations were associated with development of complications (p = 0.01) and death (p < 0.0001).
Conclusions: Procalcitonin contribution to the evaluation of CAP varies according to severity. While procalcitonin may have a role to predict the microbial etiology in patients with a low PSI score, in patients classified within high PSI risk classes, it is a prognostic marker rather than a predictor of etiology.
Similar articles
-
Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.Respir Care. 2014 Apr;59(4):564-73. doi: 10.4187/respcare.02807. Epub 2013 Oct 29. Respir Care. 2014. PMID: 24170911
-
Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.Eur Respir J. 2012 May;39(5):1144-55. doi: 10.1183/09031936.00080411. Epub 2011 Nov 10. Eur Respir J. 2012. PMID: 22075489
-
Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.Respirology. 2012 Feb;17(2):330-6. doi: 10.1111/j.1440-1843.2011.02101.x. Respirology. 2012. PMID: 22059525
-
The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review.Dan Med J. 2012 Mar;59(3):A4357. Dan Med J. 2012. PMID: 22381083 Review.
-
Biomarkers and community-acquired pneumonia: tailoring management with biological data.Semin Respir Crit Care Med. 2012 Jun;33(3):266-71. doi: 10.1055/s-0032-1315638. Epub 2012 Jun 20. Semin Respir Crit Care Med. 2012. PMID: 22718212 Review.
Cited by
-
Correlation between Chest Computed Tomography Score and Laboratory Biomarkers in the Risk Stratification of COVID-19 Patients Admitted to the Emergency Department.Diagnostics (Basel). 2023 Aug 31;13(17):2829. doi: 10.3390/diagnostics13172829. Diagnostics (Basel). 2023. PMID: 37685368 Free PMC article.
-
Prognostic value of B-type natriuretic peptide for nursing- and healthcare-associated pneumonia and aspiration pneumonia in comparison with procalcitonin and A-DROP score: a prospective cohort study.Ann Transl Med. 2023 Mar 31;11(6):254. doi: 10.21037/atm-22-4151. Epub 2023 Feb 7. Ann Transl Med. 2023. PMID: 37082669 Free PMC article.
-
Predictive Value of MR-proADM in the Risk Stratification and in the Adequate Care Setting of COVID-19 Patients Assessed at the Triage of the Emergency Department.Diagnostics (Basel). 2022 Aug 15;12(8):1971. doi: 10.3390/diagnostics12081971. Diagnostics (Basel). 2022. PMID: 36010321 Free PMC article.
-
A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics.Hum Vaccin Immunother. 2021 Dec 2;17(12):5460-5474. doi: 10.1080/21645515.2021.1990649. Epub 2021 Nov 10. Hum Vaccin Immunother. 2021. PMID: 34757894 Free PMC article. Review.
-
Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial.BMJ. 2021 Sep 21;374:n2132. doi: 10.1136/bmj.n2132. BMJ. 2021. PMID: 34548312 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous